|
|
Welcome to the GSK Settlement Website
Se Habla Español Por Favor Presione Aqui
The United States District Court for the District of Massachusetts approved the settlement on July 19, 2007. However, an appeal of the settlement was filed with the United States Court of Appeals for the First Circuit in December 2007. The parties are in the process of filing their briefs with the Appeals Court and once the briefs have been filed, the Appeals Court will assign a hearing date to this matter, possibly in late summer or early fall. The appeals process is a lengthy one and we are unable, at this time, to give any specific date regarding a decision by the Appeals Court and a continuation of the claim process. In addtition, we cannot tell you at this time when checks will be distributed.
Update: The settlement was approved on July 19, 2007.
Click here to read the order
There is an Approved Settlement with GlaxoSmithKline (“GSK”), one of the Defendants in a class action lawsuit in the U.S. District Court for the District of Massachusetts. The name of the lawsuit is In re: Pharmaceutical Average Wholesale Price Litigation, Docket No. 01-CV-12257-PBS, MDL No. 1456.
The lawsuit claims that certain drug companies reported false and inflated average wholesale prices (“AWP”) for certain types of outpatient drugs. The reported AWPs are often used to set prescription drug prices that are paid by Medicare, consumers and insurers. The lawsuit asks the Court to award money damages to some people who paid or made co-payments for the drug.
GSK has agreed to pay $70 million to settle these and other related claims. A $4.5 million payment to certain State Attorneys General, as well as attorneys' fees and the costs of administering the Proposed Settlement, will be deducted from the Settlement Fund before distributions to Class Members.
The remaining fund will be distributed to consumers and insurer Class Members (including Third-Party Payors) who submit a valid claim.
If You Made or Are Obligated to Make a Percentage Co-Payment
or Full Payment for the GSK Drugs:
Kytril Injectable (Granisetron HCL)
Zofran Injectable (Ondansetron HCL)
Alkeran (Melphanan)
Kytril Tablets (Granisetron HCL)
Myleran (Busulfan)
Retrovir (Zidovudine)
Zofran Orals (Ondansetron HCL)
Zantac (Ranitidine HCL) |
Imitrex (Sumatriptan)
Lanoxin (Digoxin)
Navelbine (Vinorelbine Tartrate)
Ventolin (Albuterol) or
Zovirax (Acyclovir)
|
Please Click Here
|
If You Are a Third-Party Payor and Made
Reimbursements for the GSK Drugs:
Kytril Injectable (Granisetron HCL)
Zofran Injectable (Ondansetron HCL)
Alkeran (Melphanan)
Kytril Tablets (Granisetron HCL)
Myleran (Busulfan)
Retrovir (Zidovudine)
Zofran Orals (Ondansetron HCL)
Zantac (Ranitidine HCL) |
Imitrex (Sumatriptan)
Lanoxin (Digoxin)
Navelbine (Vinorelbine Tartrate)
Ventolin (Albuterol) or
Zovirax (Acyclovir)
|
Please Click Here
|
|
